AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca net intangible assets carrying value ($M) ($M)
Form 20-F Note 10/11 — Intangible Assets & Individual Medicine Carrying Values
Latest, FY2025
37,846
Period ended Dec 31, 2025
Change on a year earlier
+1.8%
37,177 in FY2024
History
11 years
Since FY2015
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net intangible assets carrying value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37,846 | +1.8% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 37,177 | -2.4% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 38,089 | -3.1% | Form 20-F FY2024 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | 39,307 | -7.5% | Form 20-F FY2024 Annual Report ↗ |
| FY2021 | Dec 31, 2021 | 42,492 | +102.9% | Form 20-F FY2023 Annual Report ↗ |
| FY2020 | Dec 31, 2020 | 20,947 | +0.5% | Form 20-F FY2023 Annual Report ↗ |
| FY2019 | Dec 31, 2019 | 20,833 | -5.1% | Form 20-F FY2022 Annual Report ↗ |
| FY2018 | Dec 31, 2018 | 21,959 | -16.1% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 26,188 | -5.1% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 27,586 | +21.8% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 22,646 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up net intangible assets carrying value ($m)
- Product, marketing & distribution rights — net carrying value ($M)35,934 · FY2025
- Software & IT intangibles — net carrying value ($M)1,094 · FY2025
- Other intangible assets & IPR&D — net carrying value ($M)818 · FY2025
- Gross intangible assets cost ($M)82,940 · FY2025
- Accumulated amortisation & impairment of intangible assets ($M)-45,094 · FY2025
- Medicine intangible — C5 franchise: Soliris & Ultomiris (Alexion) ($M)10,981 · FY2025
- Medicine intangible — Strensiq & Kanuma (Alexion) ($M)2,846 · FY2025
- Medicine intangible — Alexion launched & IPR&D pipeline assets ($M)1,944 · FY2025
- Medicine intangible — Calquence (Acerta Pharma) ($M)3,371 · FY2025
- Medicine intangible — Enhertu (Daiichi Sankyo alliance) ($M)3,331 · FY2025
- Medicine intangible — Datroway (Daiichi Sankyo alliance) ($M)1,020 · FY2025
- Medicine intangible — Baxdrostat (CinCor Pharma acquisition) ($M)1,291 · FY2025
- Medicine intangible — Lokelma (ZS Pharma) ($M)1,460 · FY2025
- Medicine intangible — Fusion Pharmaceuticals radioconjugates ($M)1,182 · FY2025
- Medicine intangible — Gracell Biotechnologies CAR-T ($M)975 · FY2025
- Medicine intangible — Amolyt Pharma (eneboparatide) ($M)861 · FY2025
- Medicine intangible — Airsupra (Bond Avillion) ($M)526 · FY2025
- Intangible amortisation charged to R&D expense ($M)47 · FY2025
- Intangible amortisation charged to SG&A expense ($M)4,073 · FY2025
Cite this data
StockData. (2026). AstraZeneca Net intangible assets carrying value ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/intang_net_total
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.